New drugs and new approaches for the treatment of metastatic urothelial cancer

摘要: The median survival of patients with metastatic bladder cancer treated M-VAC is approximately 1 year and long-term occurs in a small proportion patients. Recent efforts to improve the outcome transitional cell carcinoma have focused on identifying new drugs single agent activity their incorporation into platinum-based combination regimens. Paclitaxel, docetaxel, ifosfamide gemcitabine are among most active agents. A large number phase I-II trials evaluated these agents two- three-drug response observed combinations varies considerably times range from 8 20 months. better understanding molecular biology will undoubtedly influence selection therapeutic modalities. Molecular targeted molecule therapy monoclonal antibodies begun dominate contemporary studies. Whether or not this approach lead results must still be determined.